The universal deregulation of c-myc gene expression in tumor cells suggests that this oncogene represents an attractive target for cancer therapeutic purposes. The same applies to the N-myc gene, which has a more restricted tissue specificity. Translocation (e.g., c-myc in Burkitt's lymphoma), or amplification (e.g., N-myc in neuroblastoma) of myc genes has been causally linked to tumor formation. Furthermore, the c-myc promoter integrates diverse mitogenic signalling cascades, which are constitutively activated in tumor cells, and translates them into expression of the c-MYC transcription factor, which promotes cell proliferation by regulating the expression of numerous target genes. Recent experimental data suggest, that even a brief inhibition of c-myc expression may be sufficient to permanently stop tumor growth and induce regression of tumors. Attempts to identify specific inhibitors of c-MYC/MAX dimerization have yielded promising results. In addition, downstreamtarget genes of c-MYC represent attractive targets for tumor therapy. Tumor cells expressing c-MYC at elevated levels are sensitized to treatment with DNA-damaging drugs. In mice and presumably also in human patients, the successful treatment of c-myc-induced tumors with conventional chemotherapy depends on the presence of functional p53. Therefore, restoration of this pathway, which is commonly lost in cancer cells, may enhance therapy of c-myc-induced tumors. These and other recent developments, which address the use of myc genes as therapeutic targets for cancer treatment, are discussed in this review.
INTRODUCTION
It has been broadly recognized that cancer is a disease caused by molecular alterations in either proto-oncogenes or tumor suppressor genes. In spite of the enormous increase in the knowledge about the mechanisms and molecular lesions underlying the formation of human neoplasia in the last 25 years [1] [2] [3] [4] relatively few of these findings have led to changes in the diagnosis and treatment of cancer.
As therapeutic targets, activated proto-oncogenes (i.e., oncogenes) may be more attractive than tumor suppressor genes since it is easier to inhibit an excessive activity than to restore a lost activity in tumor cells. However, the loss of tumor suppressor activity may be therapeutically exploited as has been shown by the design of a recombinant adenovirus, which preferentially eliminates p53-negative cells [5] .
The intense research on signalling pathways involved in cancer has identified a large number of potential therapeutic targets, which seem attractive for specific interference with the formation and spread of tumors. Pioneering studies have demonstrated that some of these molecular alterations can be exploited for the treatment of cancer [6] . One outstanding example is the use of humanized antibodies directed towards the oncogenic receptor tyrosine kinase HER2/neu for the treatment of breast cancer [7] . Another example is the kinaseinhibitor Gleevec, which is successfully used to treat chronic myeloid leukemia (CML) resulting from a chromosomal translocation that generates a constitutively active tyrosine *Address correspondence to this author at the Molecular Oncology, MaxPlanck-Institute of Biochemistry, Am Klopferspitz 18A, D-82152 Martinsried/Munich, Germany; Tel: ++49-(0)-89-8578-2875; Fax: ++49-(0)-89-8578-2540; E-mail: herme@biochem.mpg.de kinase (BCR-ABL). However, the later example also shows the difficulties in obtaining effective results with highly specific therapeutic means: cancer cells represent extremely heterogeneous targets, which escape therapeutic approaches through their ability to mutate and adapt to environmental pressures in relatively short time frames. Treatment of late stage patients with Gleevec resulted in relapses at a high frequency, which were due to point mutations or amplification of the BCR-ABL fusion gene. Therefore, the successful use of Gleevec has been restricted to early stages of the disease [8] .
Transcription factors have only recently come into focus as drug targets [9] . Their relative position downstream of signalling cascades, which contain the majority of oncogeneproducts, may provide the advantage of targeting of one nodal gene/gene product instead of targeting numerous different signalling molecules, and a decreased risk of therapy-resistance by up-regulation of parallel signalling pathways.
The genes encoding the MYC transcription factors appear to be especially attractive targets for genetic and pharmacological approaches since they are functionally downstream of most of the known oncogenes and are overexpressed/deregulated in most tumor types (discussed below). Therefore, inhibition of MYC function would affect a large number of different tumors.
BIOLOGY OF THE MYC PROTO-ONCOGENES Historical
The first myc gene was identified as a viral oncogene (vmyc) in the acutely transforming MC29 virus, which induces myelocytomatosis and tumors in chicken [10, 11] , similar sequences were identified in uninfected cells [12] . The cellular homolog of v-myc was identified in chicken [13] , in human [14] , and in other vertebrates as well as in higher invertebrates. The human c-myc gene was found to be the critical target of activating translocations in Burkitt's lymphoma in which c-myc expression is constitutively driven by the immunoglobulin enhancers [15] . Two closely related myc genes, L-myc and N-myc, have also been identified [16, 17] . Although these three myc genes share common properties, they are not entirely redundant [18] .
Experimental Data on MYC Genes
Homozygous deletion of c-m y c in mice leads to embryonic death at day 10 due to hematopoietic failure [19] . N-myc knock-out mice survive 1-2 days longer and show abnormalities in tissues that normally express N-myc [20] . Although L-myc shares many features with c-and N-myc, Lmyc knock out animals show no phenotype [21] . Recently, Trumpp et al. generated conditional knock out mice which allowed the analysis of the requirement of c-myc at later developmental stages [22] . This study showed that c-myc is required for proliferation of most cell types. However, proliferation of certain cell lines, although at a reduced rate, seems to be possible after deletion of c-myc [23] , or in the absence of c-MYC's dimerization partner MAX [24] , which is required for the transforming activity of c-MYC. Although, these examples seem to be exceptions, they indicate that tumors could potentially become resistant to drugs, which inhibit c-MYC function.
Ectopic expression of c-myc alone is not sufficient to generate tumorigenic cells. Other genetic alterations like coexpression of an activated ras allele are required to transform primary rodent cells. c-myc has immortalizing properties as it extends the replicative life span of primary human cells, presumably by activating the expression of the htert gene encoding the catalytic subunit of telomerase [25] . The c-myc gene is rapidly induced by a variety of mitogens, and its level of expression is generally elevated in actively proliferating cells.
By fusion of the c-MYC protein to the estrogen receptor hormone-binding domain it was possible to specifically activate c-MYC function in the absence of mitogens: these experiments showed that c-MYC is sufficient to induce entry into S-phase [26] . However, later it was observed that the mitogenic effect of c-MYC activation in cells arrested by low serum concentrations (<0.5%) is accompanied by programmed cell death [27] . Co-expression of anti-apoptotic genes, like Bcl-2, allows c-MYC expressing cells to proliferate in the absence of growth factors [28] . Ectopic c-MYC expression leads to stabilization of the tumor suppressor gene product p53 and activation of p53's proapoptotic activity [29] . Furthermore, inactivation of p53 leads to resistance against c-MYC-induced apoptosis [29] [30] [31] . A recent study suggests that ectopic c-MYC induces DNA-damage, and thereby activates p53 [32] . Another view is favoured by the studies showing that the ARF gene encoded by the tumor-suppressive gene locus, INK4A, is induced after expression of c-MYC or other mitogenic transcription factors, like E2F [33] . The authors suggest that activation of cell cycle deregulating genes is translated into activation of the ARF gene, which encodes a p53-stabilizing protein [34] . Consistent with this model, fibroblasts from ARF-/-mice are largely refractory to c-MYC-induced apoptosis [33] .
The c-MYC protein is a transcription factor with a basicregion-helix-loop-helix (BR-HLH-LZ) motif, which mediates specific DNA-binding and dimerization with the BR-HLH-LZ protein MAX. The transforming activity of c-MYC is dependent on induction of target genes, which is mediated through E-box elements in the vicinity of target gene promoters and depends on hetero-dimerization with the MAX-protein [35] [36] [37] [38] . Recently, a number of studies have shown that specific repression of gene expression by c-MYC is of similar importance for c-MYC-mediated transformation [39] . This repression is mediated by interaction of c-MYC with additional DNA-binding proteins (discussed below). Several key cell cycle inhibitory genes are repressed by c-MYC (e.g., p21, p15, p27). Thereby, deregulated c-myc expression may antagonize a number of negative growth signals (induced by e.g., TGF-β, DNA-damage, and differentiation), and contribute to unrestricted cell cycle progression and tumor-growth under conditions, which would normally result in cell cycle arrest.
c-MYC GENES IN HUMAN CANCER
c-myc is expressed at elevated levels in most tumors [40] . In addition, several tumors contain genetic alterations (i.e., translocations, gene amplifications and mutations in regulators of c-myc expression), which directly affect c-myc expression [18] . These tumor-types seem to be especially suited for therapies based on interference with MYC function and are briefly described below.
Burkitt's Lymphoma
These tumors are characterized by juxtaposition of the cmyc gene located on chromosome 8 to the regulatory elements of the immunoglobulin µ heavy chain or the λ and κ light chain genes located in chromosomes 2, 14 or 22, respectively [15] .
Burkitt's-Like Lymphoma
Patients with acquired immune deficiency syndrome (AIDS) commonly have a Burkitt's-like lymphoma. Although the c-myc translocation to IgG loci is not seen in all of these cases, the rate is still very high [41] . Furthermore, other accompanying changes typical for Burkitt's lymphoma, as p53 mutations, are also present in these tumors [42, 43] .
Colorectal Cancer
Primary human colon adenocarcinomas express 5-40x higher levels of c-myc mRNA than adjacent normal mucosa [44] . Several reports have confirmed this finding [45, 46] . In one third of these tumors, elevated c-myc levels may be due to a low level amplification of the c-myc gene (2-5 fold [47] ). The explanation for the dramatic up-regulation of cmyc expression in the majority of colorectal cancers came with the discovery that c-myc is negatively regulated by the APC/β-catenin pathway [48] , which is inactivated in virtually all cases of colorectal cancer [2] . Since 19-26% of hepatocellular carcinomas also show inactivation of this pathway [49] , it will be interesting to determine whether cmyc is also deregulated due to a defect in the APC pathway in this type of cancer.
Breast Cancer
In a study of approximately 1000 breast cancer patients, amplification of c-myc was found in 17.1% [50] . For comparison, the oncogene HER2/neu was amplified in 18.7% of the cases analyzed [50] . Berns et al. concluded that c-myc amplification has more prognostic value than HER2/neu amplification since it was highly associated with reduced relapse-free and overall survival [50] . Another report found that a group of patients with a rapid disease reoccurrence (mean disease free time: 1.4 years) or progression (mean disease free time: 1.4 years) had c-myc amplifications with a frequency of 56%, whereas patients with >6.4 years of disease free survival had a frequency of 30% c-myc amplifications. The occurrence of HER2/neu amplifications was roughly similar in both groups (19% vs. 20% [51] ). Others have provided evidence showing that cmyc is downstream of the receptor tyrosin kinase HER2/neu, which is commonly subject to oncogenic activation in breast cancer [52] .
Prostate Cancer
In prostate cancer, c-myc amplifications were detected at a frequency of 29% [53] . Mutational inactivation of the MYCantagonist Mxi-1 in prostate carcinoma may be another mechanism of MYC activation [54] . Mxi-1 inactivation would presumably shift the equilibrium between Mxi-1/MAX and c-MYC/MAX in prostate cells towards c-MYC/MAX hetero-dimers, and therefore lead to elevated expression of c-MYC-target genes. However, the frequency of Mxi-1 mutations in prostate carcinoma is relatively low [55] .
Melanoma
c-myc expression is higher in metastatic lesions compared to primary lesion and was recommended as a powerful prognostic marker for regional metastatic melanoma [56] . The recent identification of ß-catenin mutations in some melanoma cell lines [57] suggests that c-myc expression levels may be deregulated in melanoma via the same route as described for colorectal cancer [48] .
N-MYC IN HUMAN CANCER Neuroblastoma
One third of all neuroblastoma (NBL) show amplification of N-myc, which inversely correlates with prognosis [58, 59] . In fact, the absence of N-m y c amplification is still the most accepted predictor of diseasefree survival. N-and c-myc presumably use the same mechanisms to transform cells. Proof for the involvement of N -m y c in NBL came with the demonstration that neuroectodermal expression of N-myc leads to an NBL-like disease in transgenic mice [60] . It is noteworthy that tumors lacking N-myc amplification show LOH at the APC locus, which may indicate that these tumors have mutant APC/β-catenin pathways [61] . This could lead to activation of c-myc expression as shown for colorectal cancer [48] .
L-MYC IN HUMAN CANCER
Unlike c-and N-myc, the evidence for a causal involvement of L-myc activation in human cancers is limited. In SCLC the frequency of L-myc amplification is rather low (~10%), and c-as well as N-myc amplifications also occur in SCLC [18] .
MYC AS A THERAPEUTIC TARGET
An advantage of c-myc as a therapeutic target may be the fact that it is downstream of multiple converging signalling pathways, which are affected by mutations in a number of different genes in diverse types of cancer. Recent experiments with mice harboring conditional alleles of c-myc suggest that even a short inactivation of c-myc may be sufficient to stop tumor cell proliferation: Jain et al. found that upon activation of a tetracylin-inducible c-myc allele in mice, a large number of tumors develop [62] . However, inactivation of c-myc leads to differentiation of these tumors and interestingly, a subsequent reactivation of c-myc induces massive apoptosis and regression of the tumors. These results suggest that upon removal of a putative c-mycinactivating drug tumors would not start to grow again but instead would be eliminated by apoptosis. According to Bazarov et al., a complete inhibition of c-MYC function does not seem to be necessary to inhibit c-MYC-induced transformation [63] . Taken together, these studies suggest that a decrease in c-MYC activity achieved by any of the strategies discussed below could potentially inhibit tumor progression and may even lead to regression of existing tumors. c-m y c is widely expressed in regenerating compartments, like the haematopoietic system, epithelial linings of the digestive tract and the skin. Therefore, transient side effects are expected after inhibition of c-MYC function by systemic treatment. As with other tumortherapeutic approaches, inhibition of c-MYC function in tumors may be problematic because of the obstacles that tumors represent for drug-delivery. For example, vascularization is generally poor inside a tumor compared to surrounding tissues. A drug specific for the MYC protein or gene has to reach the nucleus of the target cell. This limits the approaches to small membrane permeable molecules as opposed to, e.g., antibodies targeted against receptor tyrosine kinases, which reside at the cell surface. An advantage of targeting c-MYC protein or mRNA may be their relatively short half-life of 30 minutes [64, 65] . In Figures 1 and 2 the currently conceivable strategies for therapeutically targeting MYC at the level of the gene, mRNA, or protein are depicted. 
Targeting of MYC by Anti-sense DNA Oligonucleotides
The use of antisense-oligodeoxynucleotides (aODNs) in cancer therapy, and their inherent problems have been extensively reviewed [66] [67] [68] . Several studies suggest that the specificity of the effects observed after administration of oligonucleotides targeting the translation of mRNA has to be questioned. In some cases the anti-proliferative effect could also be seen with randomized oligonucleotides or it was caused by binding of oligonucleotides to cytoplasmic signalling molecules.
An early study by Heikkila et al. employed aODNs to show that c-myc expression is required for the transition from G1-to S-phase of the cell cycle [69] . The proliferation of different tumor cell lines could be inhibited by aODNs: e.g., treatment of a Karposi-Sarcoma cell line with c-mycspecific aODNs is sufficient to block proliferation [70] .
Liposome encapsulation of c-myc-specific aODNs led to a significant improvement when used for treatment of human melanoma xenografts in mice [71] . These xenografts exhibited reduced c-myc expression, which correlated with reduced tumor-growth and prolonged survival of the mice, when compared to treatment of tumors with c-myc-specific aODNs without liposome encapsulation. Furthermore, when the treatment was combined with cisplatin complete regression of tumors was observed in ~30% of the mice with a persistence of 60 days after only one treatment.
Junghans et al. exploited the natural features of protamin to improve the up-take of c-myc specific aODNs [72] . Protamin is a small polycationic polypeptide (~4 kDa), which binds DNA and delivers it to the nucleus. Protamin has already been pharmaceutically employed for the last 30 years to deliver insulin at slow release conditions. Zhang et al. found a significantly increased up-take when using cationic liposomes to encapsulate radiolabeled ODNs [73] . By enclosing anti-GD2 in the liposomes, Pastorino et al. could achieve targeted delivery of c-myc aODNs to melanoma or neuroblastoma cells which resulted in loss of proliferative activity [74] .
Boffa et al. fused dihydrotestosterone to peptide nucleic acids (PNAs) directed against c-myc mRNA. PNAs are structural analogs of DNA or RNA. Thereby, they achieved specific nuclear transport of the PNAs and concomitant down-regulation of c-myc in a prostate cancer cell line [75] . Carrol et al. analyzed the effects of c-myc-specific aODNs on the cell cycle in breast cancer cell lines [76] . They suggest that the observed down-regulation of cyclin D1 expression is the cause for the subsequent redistribution of the cdkinhibitor p21 from cyclin D1/cdk4 complexes to cyclin E/cdk2 complexes. This would then lead to a cell cycle inhibition in the early G1 phase. Consistent with this scenario, simultaneous suppression of p21 by aODNs alleviates the effects of c-myc-specific aODNs. Interestingly, administration of the anti-estrogenic ICI 182780 induces the identical molecular changes, suggesting that the rapid suppression of c-m y c expression observed after administration of ICI 182780 is the primary mode of action of this drug [76] . Akie et al. observed a synergistic effect when combining c-myc-specific aODNs with retinoic acid (RA), a substance which generally leads to down-regulation of c-myc expression: the combination inhibited cell proliferation by 60% whereas each substance alone led to inhibition by ~20% [77] .
Targeting of MYC by Anti-sense mRNA
In two reports describing the reduction of c-MYC expression by delivery of antisense c-myc mRNA expressing virus or plasmids to tumor cells, the cells respond by undergoing apoptosis [78, 79] . These results indicate that tumor cells may be dependent on the continuous expression of c-myc and support the use of c-myc as a therapeutic target.
Targeting of MYC by Triple-Helix Forming Oligonucleotides
The triple-helix DNA-based approach relies on inhibition of gene transcription. Triple-helix forming oligonucleotides (TFOs), which are purine-rich (GA) or mixed purine-/pyrimidine-rich (GT), stably bind to duplex DNA in a sequence specific manner. The binding occurs in the major groove of the double helix with base pairing to the purinestrand of the target sequence facilitated by Hoogsteen-type hydrogen bonds. Through binding to homopurine strands in promoter regions, TFOs can prevent the binding of activating transcription factors. In case of c-myc a sequence near the P2-promoter, which gives rise to ~75-90% of c-myc mRNA, was used for the TFO approach by McGuffie et al. to prevent binding of E2F, MAZ and ets transcription factors [80] . In order to confer increased resistance to nucleases, TFOs were synthesized with phosphorothioate internucleotide linkages. By immunofluorescence analysis, it was shown that these oligos remained intact for at least 72 hours. Several leukaemia and lymphoma cell lines were treated with these TFOs in vitro. As with antisense c-myc mRNA, the tumor cells arrested and then underwent apoptosis, whereas control TFOs had no effect. The same group designed and tested a novel TFO specific for the c-myc P2 promoter with parallel and anti-parallel binding motifs resulting in an increased affinity [81] . Thereby, the effective concentration could be reduced to 1 µM, which may be more realistic for in vivo applications than the previously used concentrations.
Targeting of MYC by Quadruplex-Forming Oligonucleotides
The active c-myc promoter is characterized by a nuclease hypersensitive site up-stream of the P2-promoter, which overlaps with a specific secondary structure (Fig. (1) ). The sense-strand of this DNA-region is guanine-rich and forms a so-called G-quadruplex when single stranded, whereas the complementary strand forms so-called I-motifs. aODNs specific for this region show inhibitory effects on cells overexpressing c-myc when used at nanomolar concentrations [82] . Simonsson and Henricksson suggested a dual mode of action for these aODNs [82] . One function of the oligo is to prevent binding of hnRNP K to the complementary strand and thereby preventing access of the Pol II complex to the cmyc promoter. On the other hand, the oligonucleotide itself forms a G-quadruplex and thereby sequesters other important factors (hnRNP A/B) necessary for activation of c-myc transcription. The use of secondary DNA structures as molecular targets for cancer therapy is discussed in detail by Hurley [83] .
Targeting of MYC by Ribozymes
c-myc-or v-myc-specific ribozymes encoded by retroviral vectors have been used to effectively down-regulate myc genes [84, 85] . Similar to the observations with other approaches, down-regulation of c-myc by ribozyme expression led to apoptosis of the transfected tumor cells. However, as in the case of all approaches discussed here, it is unclear which mode of delivery can assure targeting of a sufficient number of, or even all, tumor cells.
Targeting of MYC by RNA Interference
This recently introduced technique holds great promise for gene specific cancer therapy [86] . Initial studies in mice targeting ras show that RNA interference can also be used to treat tumors in vivo [87, 88] .
Inhibition of MYC Expression with Small Molecule Drugs
It may be hard to identify drugs which specifically downregulate c-myc, since a screen based on repression of c-myc would yield a large number of inhibitors of up-stream mitogenic signalling cascades. Down-regulation of c-myc would be a secondary effect in those cases. An example for this principle may be a substance originally identified as an inhibitor of src kinase [89] , which effectively inhibits c-myc expression. Interestingly, the negative effects of this inhibitor on PDGF-β induced cell cycle progression are antagonized by c-myc expression [89] , showing that c-myc induction is required for cell cycle effects mediated by the PDGF-β/src pathway.
The iron chelator desferoxamine mesylate (DFO) was found to selectively down-regulate N-myc in neuroblastoma cell lines [90] . The inhibition of N-myc by DFO occurs at the level of transcriptional initiation and the neuroblastoma cell lines treated with DFO undergo apoptosis. Fan et al., suggest that DFO could be used as an adjunct to current therapy.
As mentioned above, treatment of estrogen dependent breast cancer cell lines with the anti-estrogen ICI 182780 results in molecular changes that are identical to those observed after treatment with a c-myc-specific aODN [76] . Therefore, Carroll et al. suggest that the primary mode of ICI 182780 action is the rapid suppression of c-m y c expression. Interestingly, ICI 182780 showed efficacy in early clinical trials for treatment of breast cancer [91] .
In tumors hypomethylation of the c-myc gene may lead to its deregulated expression [92] . Therefore, it was suggested that restoration of CpG-methylation in the c-mycpromoter might have therapeutic value. Folate, or folic acid are the main methyl group donors. Accordingly, a folate rich diet may contribute to cancer prevention, since it prevents hypomethylation [93] .
Recently, Wilson et al. devised a novel technique, which allows the microscopic visualization of drug-effects on c-myc expression and transcript elongation at the single cell level [94] . By using fluorescent probes against different parts of the c-myc mRNA, it was possible to distinguish between inhibition of transcriptional initiation and elongation. The authors used the short chain fatty acid butyrate as an example: in colon cancer cells this substance induced elevated transcriptional initiation of c-myc, however a block to transcriptional elongation resulted in reduced overall cmyc expression. The authors suggest, that this kind of approach should facilitate the cell-based screening for inhibitors of c-myc expression.
Inhibition of MYC/MAX Dimerization
Transformation by c-MYC is dependent upon dimerization with the HLH-LZ protein MAX, since c-MYC/MAX heterodimers facilitate binding of c-MYC to Eboxes in the vicinity of target genes (Fig. (2) ), which mediate the oncogenic effects of c-MYC [95, 96] . Therefore, it seems reasonable to interfere with the dimerization of c-MYC and MAX. In favour of this strategy is the observation that the MYC/MAX heterodimer is relatively unstable [97] . Kohlhuber et al. tested the effect of a truncated, dominantnegative c-MYC after microinjection of the respective plasmids [98] . They found that expression of the HLH-LZ domain of c-MYC leads to rapid induction of apoptosis. Giorello et al. generated a peptide corresponding to helix 1 of the c-MYC helix-turn-helix motif fused to a proteininternalization domain [99] . This peptide was able to interfere with c-MYC functions, as induction of cell proliferation and transactivation of ODC at a concentration of 1-10 µM. In a more recent study these authors used a retro-in-verso peptide also corresponding to helix-1 of c-MYC [100, 101] : this peptide was 5-10 fold more effective and 30 times more stable in culture medium than the previously used peptide and may therefore be tested in animal studies in the future.
The c-MYC protein does not form homodimers in vivo. Soucek et al. found that small regions in the c-MYC leucine-zipper are critical for mediating this heterodimerization specificity: mutation of four amino-acids in the leucine-zipper of c-MYC is sufficient to allow c-MYC homodimerization [102] . Heterodimers between this mutant form of c-MYC (Omomyc) and c-MYC are unable to bind to DNA. Furthermore, Omomyc interferes with cellular proliferation. Therefore, Soucek et al. suggest that interfering with the dimerization specificity of c-MYC using small peptides encompassing the mutant leucine-zipper of Omomyc may be of therapeutic value.
The inhibition of protein-protein interactions by small molecules is a challenging task since large interaction surfaces have to be effectively disrupted. Nonetheless, a recent study by Berg et al. suggests for the first time that such an approach may be feasible for interfering with the function of transcription factors [103] . These authors fused the BR-HLH-LZ domains of c-MYC and MAX to derivatives of the green fluorescent protein (GFP). Upon heterodimerization of MYC-CFP and MAX-YFP fusionproteins these molecules exhibited fluorescence energy transfer (FRET). This effect was employed as the read-out in an in vitro assay. After screening a library of ~10,000 peptido-mimetic substances four candidates, which inhibit MYC/MAX heterodimerization, were identified. Two of these substances were also able to inhibit c-MYC-induced transformation in chicken embryo fibroblasts. However, they also inhibited transformation by either src or JUN. In the case of the inhibition of JUN-induced transformation, it is possible that the identified substance generally interferes with dimerization of leucine-zippers, since JUN dimerizes through this motif with other leucine-zipper containing factors as FOS. Another unanswered issue is the potential effect of these substances on hetero-dimerization of MAX with other HLH-LZ proteins, such as MAD, Mxi-1 and Mnt, which are antagonists of c-MYC-induced transformation. However, the agents identified by Berg et al. are the first lead compounds, which can now be developed to identify more effective small molecule inhibitors of c-MYC/MAX heterodimerization.
Targeting of Additional c-MYC Protein Interactions and c-MYC-Associated Enzymes
Transformation by c-MYC depends on several additional protein-protein interactions, besides the interaction with MAX [36] . These interactions may also represent potential targets for pharmacological interference in the future (see Fig. (2) ). Recently, the interaction between MIZ-1 and MYC has been implicated in a number of cancer-relevant scenarios [104] [105] [106] . MIZ-1 binds to the initiator element (INR) in several genes repressed by c-MYC. These INR-containing genes, as p15 or p21, are activated by MIZ-1 via association with the co-factor p300. However, binding of c-MYC to MIZ-1 displaces p300 and leads to repression of INRcontaining genes. Selective elimination of the MYC/MIZ-1 interaction by specific point mutations is sufficient to prevent c-MYC-mediated repression of the p21 gene [104] , which encodes a Cdk-inhibitor. Disruption of the MYC/ MIZ-1 interaction may therefore represent an attractive therapeutic approach in the future.
The binding of several different proteins to the Nterminal regions of the c-MYC protein is essential for c-MYC-mediated transformation [36] . Among these proteins are TRRAP, TIP48/49 and BAF53 [107] [108] [109] , which are involved in chromatin remodelling: TIP48 and TIP49 are ATP-dependent helicases, whereas TRRAP recruits the histone acetylase GCN5 to c-MYC-regulated promoters [110] . TRRAP, TIP48/49 and BAF53 possess or recruit enzymatic activities, which represent attractive targets for pharmacological interference. The targeting of c-MYCassociated enzymes may be more effective than the inhibition of protein-protein interactions mentioned above.
Viral Expression of MYC Antagonists
Since c-MYC is part of a transcription factor network, which also includes natural antagonists of c-MYC, several laboratories have studied the effect of ectopic expression of these genes on tumor cells. Indeed, adenoviral overexpression of Mad in human hepato-carcinoma cells was sufficient to inhibit proliferation in culture, and tumor formation in mice [111] . Similar results were obtained in prostate carcinoma cells with an adenovirus encoding Mxi-1 [112] . In order to achieve specific repression of c-MYCregulated genes, Berns et al. went one step further and replaced the transactivation domain of c-MYC by the Sin3-domain of Mad, which recruits a histone deacetylase complex [113] . Expression of this molecule induces a G1-arrest through repression of c-MYC-regulated genes and may therefore have therapeutic potential.
Inhibition of MYC Target Genes
Since c-MYC-induced transformation is presumably the result of specific induction of c-MYC target genes, inhibition of the encoded products of these genes should be an effective means to inhibit tumor growth. For example, it has been shown that cells derived from mice deficient for the c-MYC target gene Id2 are resistant to c-MYC-induced transformation [114] . A number of studies have been performed to identify c-MYC-induced genes [115] . Some of these were conducted in human cell systems [116, 117] . Serial analysis of gene expression (SAGE) has several advantages when compared to other methods of genome wide experssion analysis [118] . We employed SAGE to identify 476 genes regulated by c-MYC in primary human endothelial cells [116] . Among these genes were 216 induced c-MYC target-genes, which may include attractive drug targets for inhibition of tumor-vascularization. For example the MetAP2/p67 gene was identified, which encodes the target for the anti-angiogenic substances TNP-470 or fumagillin, which are currently being tested in clinical trials [119] . Another relevant c-MYC-induced drug target may be cyclin dependent kinase (cdk) 4 [120] . Small molecule inhibitors of cdks are being tested for treatment of various tumor types [121] .
The targeting of c-MYC-induced genes to treat tumors displaying high c-MYC levels may however be complicated by the fact that several of the large number of c-MYCinduced genes participate in the oncogenic activity of c-MYC.
STRATEGIES FOR EXPLOITING MYC FUNCTION IN TUMORS

MYC-Driven Transcription
Since most human tumors display elevated c-MYC activity it has been proposed that transcriptional activation by c-MYC can be exploited to produce tumor selective toxicity. This can be achieved by placing genes encoding either detrimental proteins (e.g., pro-apoptotic genes) or prodrug converting enzymes (e.g., thymidine kinase) under the control of MYC-binding DNA-elements (E-boxes). After delivery of these genes to the site of the tumor, ideally only tumor cells should express these cassettes, and undergo cell death due to the expression of c-MYC at high levels. Several groups have attempted to use this strategy in vitro and in vivo. Kumagai et al. placed a HSV-TK gene under the control of four E-boxes [122] . Small cell lung cancer (SCLC) cell lines expressing this construct showed a specific inhibition of xenograft-growth by ~90% which was accompanied by a "bystander-effect" after treatment with Ganciclovir (GCV). When the c-MYC-regulated TK gene was integrated into an adenoviral vector injection of this virus in combination with GCV administration markedly suppressed the growth of c-MYC-overexpressing tumors in mice [123] . This effect was not observed in tumors expressing MYC at low levels. Pawlik et al. used a similar strategy to exploit the over-expression of N-MYC in neuroblastoma [124] . The rabbit liver carboxylesterase, which activates the pro-drug CPT-11, was placed under the control of the ODC promoter, which contains several Eboxes known to be occupied by c-MYC. A ten-fold increase in sensitivity to CPT-11 was observed after adenoviral delivery of this construct to neuroblastoma cell lines. Iyengar et al. further optimized this so-called viral-directed enzyme pro-drug therapy (VDEPT) by analyzing various combinations of E-boxes and promoters to achieve selectivity for MYC-expressing tumors [125] . A construct with six ODC-derived E-boxes up-stream of the ODCpromoter showed the highest specificity for c-MYCexpressing tumors.
MYC-Induced Apoptosis
Several studies suggest that cells expressing MYC at high levels or in a deregulated fashion are sensitized to undergo apoptosis by stimuli that would induce cell cycle arrest otherwise (e.g., DNA-damage, hypoxia [126] [127] [128] [129] ). Whether this effect is due to specific activation of apoptotic effector genes by c-MYC or a result of unscheduled, c-MYCinduced cell cycle progression, is still a matter of debate. As discussed above, the p53 tumor suppressor gene is critical for mediating c-MYC-induced apoptosis [29] [30] [31] . Schmitt et al. could demonstrate that the apoptotic capacity of p53 is the function that is selected for by mutation of p53 during progression of c-myc-induced tumors in vivo [130] . In addition, it has been observed that c-MYC activation itself can induce DNA-damage, which could also be a reason for the increased likelihood of apoptosis in c-myc overexpressing cells [32] . For therapeutic purposes detection of c-MYC levels in tumors may be useful to predict the outcome of treatment with DNA-damaging agents (i.e., chemo-or radiation-therapy). The requirement of p53 for efficient MYC-induced apoptosis after DNA-damage can also be found in colorectal tumors [131, 132] . Therefore, the recently identified substances, which restore p53 function [133] , may enhance apoptosis in tumors expressing high levels of c-MYC.
PERSPECTIVES
The advent of new technologies and improvement of already established approaches, like cell-based high throughput screening and rationale drug design, may allow the conversion of the knowledge that has been obtained about myc genes and their products into tailored therapies. The recent identification of specific small molecule inhibitors of MYC/MAX dimerization should permit further optimization and validation of a MYC protein-based tumor therapy. Furthermore, improved tumor diagnostic tools may lead to routine determination of alterations in myc genes, myc expression and of MYC-target gene expression. In addition, the status of genes influencing MYC-induced apoptosis may be determined. These data should allow selection of a specific form of therapy, which exploits the deregulated expression of myc genes in human tumors.
NOTE ADDED IN PROOF
While this manuscript was reviewed the x-ray structure of c-MYC/MAX co-crystal encompassing the heterodimerization and DNA-binding domains was published [134] . The new details of the c-MYC/MAX structure reveal several new target structures for pharmacological interference. For example the formation of c-MYC/MAX tetrameres by two c-MYC/MAX dimers could serve as a therapeutic target. Furthermore, MAX/MAX homodimers display a packingdefect in the leucine-zipper interaction domain, explaining why it is less stable than the c-MYC/MAX heterodimer. Artificial stabilization of the MAX-homodimer by correcting this packing-defect using small molecules may be an interesting strategy to inhibit c-MYC function. 
